Agenerase is a drug owned by Glaxosmithkline. It is protected by 4 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 11, 2017. Details of Agenerase's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6730679 | Pharmaceutical formulations |
Nov, 2017
(7 years ago) |
Expired
|
| US5723490 | THF-containing sulfonamide inhibitors of aspartyl protease |
Mar, 2015
(9 years ago) |
Expired
|
| US5646180 | Treatment of the CNS effects of HIV |
Jul, 2014
(10 years ago) |
Expired
|
| US5585397 | Sulfonamide inhibitors of aspartyl protease |
Dec, 2013
(10 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Agenerase is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Agenerase's family patents as well as insights into ongoing legal events on those patents.
Agenerase's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Agenerase's generic launch date based on the expiry of its last outstanding patent is estimated to be Nov 11, 2017 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Agenerase Generics:
There are no approved generic versions for Agenerase as of now.
Alternative Brands for Agenerase
Agenerase which is used for managing HIV infection., has several other brand drugs in the same treatment category and using the same active ingredient (Amprenavir). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie |
| |||||||||||||||
| Agouron Pharms |
| |||||||||||||||
| Bristol Myers Squibb |
| |||||||||||||||
| Gilead |
| |||||||||||||||
| Gilead Sciences |
| |||||||||||||||
| Gilead Sciences Inc |
| |||||||||||||||
| Msd Sub Merck |
| |||||||||||||||
| Viiv Hlthcare |
| |||||||||||||||
About Agenerase
Agenerase is a drug owned by Glaxosmithkline. It is used for managing HIV infection. Agenerase uses Amprenavir as an active ingredient. Agenerase was launched by Glaxosmithkline in 1999.
Approval Date:
Agenerase was approved by FDA for market use on 15 April, 1999.
Active Ingredient:
Agenerase uses Amprenavir as the active ingredient. Check out other Drugs and Companies using Amprenavir ingredient
Treatment:
Agenerase is used for managing HIV infection.
Dosage:
Agenerase is available in the following dosage forms - solution form for oral use, capsule form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 150MG | CAPSULE | Discontinued | ORAL |
| 50MG | CAPSULE | Discontinued | ORAL |
| 15MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLUTION | Discontinued | ORAL |